Citi analysts forecast 19% earnings growth for the healthcare sector in 2025 amid improving fundamentals and a boom in weight ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...

The latest health news includes WuXi's sale of its Advanced Therapies unit due to US restrictions, expanding famine in Sudan ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

Novo Nordisk, Dragon Edge Group, Global Payments, Universal Robina Corp., AIA Philippines and Diversey were recognized as the ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

The pharmaceutical industry in Denmark has grown rapidly in recent years. This paper discusses the macroeconomic impact of the pharmaceutical sector. The analysis focuses on Novo Nordisk, the leading ...

The first round of the U.S.’ Medicare negotiations accounted for a lot of digital ink and headlines in 2024. Next year is sure to bring more of the same as Medicare is to announce up to 15 Part D ...

The coffee chain's stock ticked up from a two-month low clocked Friday when its union announced [a five-day walkout across multiple cities]( ...